Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases.

Area of Science:

• Biochemistry
• Immunology
• Gastroenterology

Background:

• Inflammatory processes involve n-6 PUFA arachidonic acid (AA) and n-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
• EPA and DHA, found in fish oil, counteract AA's inflammatory effects by inhibiting eicosanoid production and generating less inflammatory mediators.
• n-3 PUFAs also influence leukocyte chemotaxis, inflammatory cytokine production, and gene expression via transcription factor activity.

Purpose of the Study:

• To explore the anti-inflammatory mechanisms of n-3 PUFAs (EPA and DHA).
• To review the effects of fish oil on inflammatory processes, particularly in the context of inflammatory bowel diseases (IBD).

Main Methods:

• Review of scientific literature on fatty acids, inflammation, and fish oil supplementation.
• Analysis of studies involving animal models of colitis and human clinical trials in IBD patients.

Main Results:

• Fish oil demonstrated reduced colonic damage, inflammation, weight loss, and mortality in animal colitis models.
• In IBD patients, fish oil supplementation led to n-3 PUFA incorporation into gut mucosa and altered inflammatory mediator profiles.
• Clinical outcomes in patients showed variable effects, with some studies reporting improved histology, reduced disease activity, corticosteroid use, and relapse rates.

Conclusions:

• n-3 PUFAs (EPA and DHA) possess significant anti-inflammatory properties through multiple pathways, including lipid mediator modulation and gene expression changes.
• Fish oil supplementation is a potential therapeutic strategy for inflammatory bowel diseases, offering benefits in gut mucosal healing and disease management, though clinical responses vary.